Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
diphtheria toxoid + tetanus toxoid + acellular pertussis vaccine + hepatitis B vaccine + haemophilus influenzae type b conjugate vaccine
- Development stage
- Unknown
- Lead developer
- Merck
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
diphtheria toxoid + tetanus toxoid + acellular pertussis vaccine + hepatitis B vaccine + haemophilus influenzae type b conjugate vaccine is a pharmaceutical combination vaccine administered to infants and young children to provide active immunization against five serious diseases: diphtheria, tetanus, pertussis (whooping cough), hepatitis B, and invasive disease caused by Haemophilus influenzae type b. This pentavalent vaccine stimulates the immune system to generate protective antibodies against each targeted pathogen, thus preventing morbidity and mortality associated with these diseases. Its primary indication is routine childhood immunization beginning as early as 6 weeks of age. The vaccine combines toxoid and conjugate technologies, leveraging safe, inactivated bacterial components (diphtheria and tetanus toxoids, acellular pertussis antigens) and a conjugated polysaccharide for Hib to elicit robust immune responses[1][2][3][4].
- Brand names
- Vaxelis
- Other names
- DTaP-HepB-HibDTwP-HepB-Hibpentavalent vaccine5-in-1 vaccine
02
Targets
Diphtheria toxinHBsAg (Hepatitis B surface antigen)
Beyond the preview
Go deeper on diphtheria toxoid + tetanus toxoid + acellular pertussis vaccine + hepatitis B vaccine + haemophilus influenzae type b conjugate vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on diphtheria toxoid + tetanus toxoid + acellular pertussis vaccine + hepatitis B vaccine + haemophilus influenzae type b conjugate vaccine.